Icon

SAXENDA (nda206321)- (18MG/3ML (6MG/ML))

LIRAGLUTIDE NOVO
18MG/3ML (6MG/ML)
Yes No
3026-Aug-03 2015-Jan-25
None 2017-Jan-25
None No
SAXENDA is a glucagon like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: Adult patients with an initial body mass index (BMI) of • 30 kg/m2 or greater (obese), or • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). Pediatric patients aged 12 years and older with: • body weight above 60 kg and • an initial BMI corresponding to 30 kg/m2 for adults (obese) by international cut-offs.
0 0 0
Total Other Developers 23
Drugs with Suitability No
18MG/3ML (6MG/ML) ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.